---
schema_version: "secwatch.filing_event.v1"
accession: "0000899923-23-000031"
form_type: "8-K"
ticker: "MYGN"
cik: "0000899923"
company_name: "MYRIAD GENETICS INC"
filed_at: "2023-05-03T23:59:59+00:00"
generated_at: "2026-06-16T02:14:13.504859+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Myriad Genetics Q1 revenue $181.2M (+10% YoY); raises FY23 revenue guidance midpoint

## Summary
- Q1 GAAP EPS $(0.67); adjusted EPS $(0.21); revenue $181.2M (+10% YoY).
- Testing volumes +21% ex-SneakPeek; hereditary cancer +24%, GeneSight +31% YoY.
- FY23 revenue guidance raised to $730-750M (previous $720-750M); gross margin 68-70% reaffirmed.
- GAAP gross margin 67.3% (down 360bps YoY) due to product mix and $12.4M prior-year benefit.
- Ended Q1 with $109.1M cash, no debt; management targets profitability by Q4 2023.

## SEC filing metadata
- accession: 0000899923-23-000031
- form_type: 8-K
- ticker: MYGN
- cik: 0000899923
- company_name: MYRIAD GENETICS INC
- filed_at: 2023-05-03T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/899923/000089992323000031/0000899923-23-000031-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/899923/000089992323000031/mygn-20230503.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000899923-23-000031
- JSON: https://secwatch.observer/filing/0000899923-23-000031.json
- Plain text: https://secwatch.observer/filing/0000899923-23-000031.txt

## Key facts
- Earnings Releases
  MYRIAD GENETICS INC reported the three months ended March 31, 2023 results: EPS $(0.67). Guidance raised.
  - Period: the three months ended March 31, 2023
  - EPS: $(0.67)
  - Guidance: raised
  - Result: reported results
  source text: Myriad Genetics Reports First Quarter 2023 Financial Results; Achieves 10% Revenue Growth Year-Over-Year, the Second Consecutive Quarter of Double-Digit Year-Over-Year Revenue Growth; Raises Mid-Point of 2023 Revenue Guidance Range
  evidence_url: https://www.sec.gov/Archives/edgar/data/899923/000089992323000031/0000899923-23-000031-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.